When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant multiple myeloma — works better than Darzalex (daratumumab) at significantly delaying disease progression or death among…
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to be used earlier in the treatment of difficult-to-manage multiple myeloma. Abecma currently is FDA-approved for adults with relapsed or refractory multiple myeloma (RRMM) who…
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos Sciences’ trispecific antibody — a treatment that simultaneously targets three proteins. This study (NCT05862012) aims to recruit up to 80 adults with relapsed or…
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly diagnosed high-risk multiple myeloma and smoldering multiple myeloma. Smoldering multiple myeloma is an early, slow-growing blood cancer that can develop into active multiple…
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral combination of Xpovio (selinexor) plus dexamethasone in people with difficult-to-treat multiple myeloma. Under the terms of a trial collaboration and supply agreement,…
Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but overall survival rates were similar between hard-to-treat Black, Hispanic, and white patients, a new U.S. study found. “We see that Black and white patients with multiple…
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be conditionally approved for treating people in Europe with relapsed or refractory multiple myeloma (RRMM). The recommendation, from the EMA’s Committee for Medicinal Products…
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a U.S. study shows. “We knew from prior studies that patients with multiple myeloma and diabetes have lower survival rates. But what we did not know…
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the corticosteroid, according to data from a Phase 3 clinical trial. Results from the trial, dubbed CANOVA (NCT03539744), also showed that the Venclexta combo was…
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and feasible for multiple myeloma patients when given around the time of an autologous stem cell transplant (ASCT). These are the findings of a…
Get regular updates to your inbox.